奥浦迈: 奥浦迈：关于发行股份及支付现金购买资产并募集配套资金报告书（草案）修订说明的公告

Group 1 - The company plans to acquire 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds from no more than 35 specific investors [1][2] - The company has received an inquiry letter from the Shanghai Stock Exchange regarding the disclosure of the restructuring draft and has actively organized discussions to address the questions raised [1][2] - The company has completed responses to the inquiry letter and has updated the restructuring report to include necessary disclosures and clarifications regarding the transaction and its associated risks [2] Group 2 - The restructuring report has been revised to include details on the decision-making and approval processes that still need to be fulfilled for the transaction [2] - The report also clarifies the specific relationships and agreements between the parties involved in the transaction [2] - Minor adjustments have been made to the restructuring report's content without affecting the overall transaction plan [2]